THERAVECTYS launches its new website & wins Deloitte’s Technology Fast50 2014 Biotech d’Avenir

PARIS - Dec. 15, 2014 - PRLog -- THERAVECTYS wins Deloitte Technology Fast 50 “2014 Biotech d’Avenir”, a prize awarded to one of the fastest-growing, most innovative & dynamicbiotech company of the year. In addition, THERAVECTYS is proud to announce the launch of its responsive & easy-to-navigate website www.theravectys.com featuring new sections & content.

A special prize granted by Deloitte Technology Fast50

Over the last 13 years, this annual event has gathered French leading actors to recognize the fastest-growing companies and the most successful fundraisers of the year.

For the first time since its creation, Deloitte Technology Fast50 showcased Biotech & Medtech and granted THERAVECTYS with the “Biotech d’Avenir” award in recognition of its continuous efforts to develop innovative therapeutic vaccines and immunotherapies in cancer & infectious diseases.

“We are convinced that all rewarded companies are spear-heading tomorrow’s economic activity and are the catalysts of a dynamic growth leading to jobs and value," said Ariane Bucaille & Vincent Gros, both Partners of Deloitte Technology Fast50.

A new, trendy & highly-functional website

THERAVECTYS enjoys an entirely new website inspired by the company’s logo and graphic chart featuring current design trends. With its light-colored background, large pictures for a maximum graph-effect and animated colored icons, the website offers a pleasant and easy way to navigate.

Seven sections are reachable from the header menu and are supplemented by linked information reachable through the footer, including links to the main social networks. The highly-functional design allows an easy access to company’s Vision and Mission as well as a detailed review of its technology platform, ongoing programs and agenda.

Discover THERAVECTYS cutting-edge technology in “Our Science” and navigate through the many sections such as “Technology” where you will learn everything about lentiviral vectors and their mode of action, “Manufacturing” will take you through the process development of new vaccine candidates for clinical trials. Other Chapters such as “Our Pipeline” and “Clinical Trials” will provide you with a detailed overview of the company’s R&D activities and pipeline across a variety of indications as well as regular updates on ongoing clinical trials.

About Theravectys

THERAVECTYS is privately-owned, fully-integrated discovery and clinical development biotech company originating from the Pasteur Institute.

THERAVECTYS capitalizes over 15 years of fundamental research in the field of lentiviral vectors and has secured worldwide exclusive rights to Pasteur Institute (http://www.pasteur.fr/) intellectual property.

Based on its lentiviral vector technology platform, THERAVECTYS develops therapeutic vaccines and immunotherapies to fight cancers and infectious diseases, including a proprietary and differentiated CAR T-cell technology platform.

The company is strongly supported by renowned investors and former global biopharmaceutical executives and is rapidly progressing in its R&D activities and in-house GMP production capabilities.

Alone and in collaboration with partners, THERAVECTYS is accelerating its clinical development programs and is planning to initiate two additional phase I/II clinical trials in oncology in 2015.

About Deloitte

Deloitte (http://www2.deloitte.com/) is the brand under which tens of thousands of dedicated professionals in independent firms throughout the world collaborate to provide audit, consulting, financial advisory, risk management, tax and related services to select clients. These firms are members of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”).